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Abstract
Background: Coronary artery disease (CAD) is the leading cause of mortality in hypertensive patients. Systematic 
Coronary Risk Evaluation (SCORE) is the preferred scoring system to predict future fatal cardiovascular events in 
hypertensive patients. However, the relationship between SCORE and coronary atherosclerosis is not well described. 
We aimed to investigate whether SCORE has a relationship with CAD severity in hypertensive patients, even in the 
absence of high risk features.
Material and methods: Four hundred and fifty-two hypertensive patients who underwent elective coronary angiog-
raphy and defined as low or moderate risk according to SCORE were included into the study. Patients were divided 
into two groups. Patients with a SCORE < 1% were defined as low risk group, and patients with a SCORE ≥ 1% 
and < 5% were defined as moderate risk group. The groups were compared regarding CAD severity.
Results: The frequency of stenotic CAD and multivessel disease, and mean SYNTAX score, were significantly 
higher in SCORE ≥ 1%, and < 5% group compared to patients with SCORE < 1%. Correlation analysis revealed a 
significant positive moderate correlation between SCORE and SYNTAX score (Pearson’s r: 0.679, p < 0.001). ROC 
curve analysis demonstrated that a SCORE ≥ 3% predicted SYNTAX score > 22 with a sensitivity of 75% and a 
specificity of 86.5% (AUC: 0.879, p < 0.001). Furthermore, multivariate analysis demonstrated that SCORE was 
an independent predictor of stenotic CAD (OR: 1.616, p < 0.001), multivessel disease (OR: 1.913, p < 0.001), and 
SYNTAX score > 22. (OR: 1.817, p < 0.001).
Conclusion: Our results suggest that SCORE is associated with CAD severity in hypertensive patients even in the 
absence of high risk features. The SCORE system may be useful in further risk stratification of hypertensive patients 
with moderate risk features and suspected CAD.
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Introduction
Hypertension is an important risk factor for both 
structural and functional damage in cardiovascular 
system that leads a significant increase in morbidity 
and mortality [1, 2]. Atherosclerosis is the main man-
ifestation of hypertension-related vascular injury, and 
coronary artery disease (CAD) is the most dangerous 
consequence of hypertensive end-organ damage and 
is the leading cause of mortality in hypertensive pa-
tients [3, 4]. Hereby, risk stratification of hypertensive 
patients remains the cornerstone of the adequately 
prevention of future cardiovascular events. Systematic 
Coronary Risk Evaluation (SCORE) system is a vali-
dated scoring system that predicts the 10-year risk of 
a first fatal atherosclerotic cardiovascular event, in re-
lation to age, gender, smoking, total cholesterol, and 
systolic blood pressure (SBP) [5]. European guide-
lines strongly recommend to use SCORE system for 
cardiovascular risk assessment of hypertensive patients 
except those who are at high or very high risk due to 
known cardiovascular disease (CVD) or associated 
conditions [4, 6]. However, SCORE only predicts the 
10-year risk of a first fatal atherosclerotic cardiovascu-
lar event, and its association with CAD and CAD se-
verity in low and moderate risk hypertensive patients 
remains unclear. Since the CAD is the leading cause 
of the death in hypertensive patients, definition of 
association of SCORE with CAD severity may pro-
vide useful information for further risk assessment in 
clinical practice, in particular, in hypertensive patients 
with low and moderate risk.
SYNTAX score is an angiographic tool that is cal-
culated based on anatomical location and potential 
functional importance of coronary lesions and is 
used to estimate the extend, complexity and severity 
of CAD [7]. SYNTAX score is the cornerstone of the 
classification of CAD severity and is an important 
prognostic factor in patients with CAD [8]. There-
fore, in the present study, the association of SCORE 
system with CAD severity in hypertensive patients 
who don’t have high risk features was investigated. 
We mainly aimed to investigate whether SCORE has 
a relationship with SYNTAX score in hypertensive 
patients classified as being at low and moderate risk 




A total of 525 consecutive hypertensive patients 
who were between the age 40 and 65 and at low or 
moderate risk according to SCORE system, and un-
derwent elective diagnostic coronary angiography 
from January 2015 to November 2019 were en-
rolled. Among these patients, 73 patients (patients 
with left ventricular hypertrophy (LVH), microal-
buminuria, and retinopathy) were excluded due to 
presence of asymptomatic hypertension-mediated 
organ damage that increases the cardiovascular risk 
independently. As a consequence, the remaining 
452 hypertensive patients were included into the 
study. Since the SCORE system is validated for 
the subjects between the age 40 and 65, patients 
younger than 40 years and older than 65 years were 
not screened for the study. Patients with established 
CVD or its equivalent or at high (SCORE ≥ 5% 
and < 10%) or very high (SCORE ≥ 10%) risk were 
also excluded at baseline and were not screened for 
the study. 
Hypertension was defined as SBP ≥ 140 mm Hg 
and/or diastolic blood pressure ≥ 90 mm Hg in re-
peated measurements, and/or known treatment with 
antihypertensive medications. Active smoking was 
defined as the current regular use of cigarettes. All 
patients were evaluated with a detailed anamnesis, 
cardiac and systemic physical examination, elec-
trocardiography and echocardiography. Laboratory 
analyses were performed from venous blood samples 
obtained after an overnight fasting. The study was 
conducted in full accordance with the Declaration of 
Helsinki and approved by the local ethics committee. 
Systematic Coronary Risk Evaluation 
(SCORE)
SCORE is the preferred scoring system to esti-
mate the 10-year risk of a first fatal atheroscle-
rotic cardiovascular event, in relation to age, gen-
der, smoking, total cholesterol, and SBP. Cardio-
vascular risk assessment with the SCORE system is 
strongly recommended for all hypertensive patients 
who are not already at high or very high risk due 
to manifest overt CVD or chronic kidney disease, 
or diabetes mellitus, or a markedly elevated single 
risk factor or LVH [4, 5]. Cardiovascular risk is 
analyzed in four groups based on SCORE. A cal-
culated SCORE ≥  10% indicates patients at very 
high risk, a SCORE ≥ 5% and ≤ 10% indicates 
patients at high risk, a SCORE ≥ 1% and < 5% 
indicates patients at moderate risk, and a SCORE 
< 1% indicates patients at low risk [4–6]. SCORE 
can be easily calculated from “SCORE charts” for 
men and women, separately. There are two sug-
gested SCORE charts for low risk and high risk 
countries, respectively. Since the study conducted 
in Turkey, we used the “SCORE — European High 
arterial hypertension 2020, vol. 24, no. 3
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Risk Chart” for calculation of SCORE [6]. In the 
present study, we divided the study population into 
two groups according to SCORE system. Patients 
with a calculated SCORE < 1% were assigned to 
the low risk, and patients with SCORE ≥ 1% and 
< 5% were assigned to the moderate risk group.
Coronary angiography and SYNTAX score
All patients underwent coronary angiography in elec-
tive conditions due to positive or suspected result of 
non-invasive tests. The classification of CAD was 
made based on coronary angiography results. Pres-
ence of ≥ 50% obstruction in any coronary artery 
was defined as stenotic CAD. Number of stenotic 
vessels and SYNTAX score were used to estimate the 
extend and severity of CAD. The presence of CAD 
was categorized as stenotic CAD (one vessel), or 
multivessel disease (MVD) according to the number 
of vessel with ≥ 50% stenosis. 
SYNTAX score is calculated for the vessels with 
a diameter > 1.5 mm and with a stenosis ≥ 50%, 
and estimates the extend, complexity and severity 
of CAD using various anatomical and functional 
parameters [7, 8]. Also, SYNTAX score is a predictor 
of adverse events in patients with CAD, and while 
a SYNTAX score ≤ 22 indicates low risk patients 
for cardiovascular events, a SYNTAX score > 22 
defines the intermediate to high risk patients [8, 9]. 
Therefore, in the present study, SYNTAX score was 
calculated for all vessels > 1.5 mm diameter and with 
a stenosis ≥ 50%, according to SYNTAX score cal-
culator (www.syntaxscore.com). All digital coronary 
angiograms were evaluated by two independent ex-
perienced cardiologists. In case of disagreement, the 
final decision was achieved by consensus.
Statistical analysis
Continuous and categorical variables were expressed 
as mean ± standard deviation and percentages, re-
spectively. The categorical variables were compared 
with the chi-square test or Fisher’s exact test. The 
normality distribution of continuous variables was 
tested with Kolmogorov-Smirnov test. Continuous 
variables between the two groups were compared 
with Student’s t test. Correlation between SCORE 
and SYNTAX score was assessed with Pearson’s cor-
relation coefficient. Receiver operating characteristics 
(ROC) curve analysis was performed to determine 
the area under the curve, and cutoff value of SCORE 
for predicting SYNTAX score >22. Multivariate lo-
gistic regression analysis was performed to define the 
independent predictors of stenotic CAD, MVD and 
SYNTAX score > 22. A p-value of < 0.05 was consid-
ered to indicate statistical significance.
Results
Among study population, 171 patients had a SCORE 
< 1%, and 281 patients had a SCORE ≥ 1%, and 
<  5%. Due to the nature of the SCORE system, 
the frequency of women (80.7%) were higher in 
patients with SCORE < 1% whereas, the frequency 
of men (68%) were higher in the SCORE ≥ 1% and 
< 5% patient groups. In the same sense, patients with 
SCORE ≥ 1%, and < 5% were older and had high-
er blood pressure levels compared to patients with 
SCORE < 1%. Also, dyslipidemia was more frequent 
in SCORE ≥ 1%, and < 5% group. Importantly, the 
frequency of stenotic CAD and multivessel disease, 
and mean SYNTAX score, were significantly higher 
in SCORE ≥ 1%, and < 5% group compared to 
patients with SCORE < 1%. Table 1 demonstrates 
the clinical, laboratory, and angiographic charac-
teristics of patients according to SCORE system. 
When comparing the patients according to SYNTAX 
score, patients with SYNTAX score > 22 were older, 
and had higher blood pressure levels compared to 
patients with SYNTAX score ≤ 22. Moreover, the 
mean SCORE was significantly higher in the group 
of patients with SYNTAX score > 22 compared to 
patients with SYNTAX score ≤ 22 (3.48 ± 1.26 vs. 
1.75 ± 1.38, p < 0.001). Table 2 shows the charac-
teristics of patients according to SYNTAX score. 
Correlation analysis revealed a significant positive 
moderate correlation between SCORE and SYN-
TAX score (Pearson’s r: 0.679, p < 0.001). Also, ROC 
curve analysis demonstrated that a SCORE ≥ 3% 
predicted SYNTAX score > 22 with a sensitivity 75% 
and a specificity 86.5% [area under the curve (AUC): 
0.879, p < 0.001] (Fig. 1)
Furthermore, multivariate logistic regression 
analysis demonstrated that SCORE was an indepen-
dent predictor of stenotic CAD [odds ratio (OR): 
1.616, 95% confidence interval (CI): 1.055–1.901, 
p < 0.001], multivessel disease (OR: 1.913, 95% CI: 
1.545–2.091, p < 0.001), and SYNTAX score > 22 
(OR: 1.817, 95% CI: 1.438–2.253, p < 0.001). 
Table 3 shows the independent predictors of stenotic 
CAD, multivessel disease and SYNTAX score > 22 in 
multivariate analysis.
Discussion
The main finding of the present article was that 
the SCORE may be useful to predict patients with 
more severe CAD and patients at relatively high risk 
for future cardiovascular events, even in the absence 
of high risk features according to SCORE system. 
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Table 2. Patients’ characteristics according to SYNTAX score
SYNTAX score £ 22
(n = 155)
SYNTAX score > 22 
(n = 64) p
Age [y] 51.4 ± 6.33 53.9 ± 5.08 0.005
Gender
   Male n (%)




14 (21.9%) < 0.001
SCORE (%) 1.75 ± 1.38 3.48 ± 1.26 < 0.001
Smoking n (%) 60 (38.7%) 24 (37.5%) 0.867
LVEF (%) 62.6 ± 4.04 61.8 ± 2.04 0.325
SBP [mm Hg] 151 ± 9.84 158 ± 10.04 < 0.001
DBP [mm Hg] 91.9 ± 5.75 97 ± 5.47 < 0.001
WBC count [× 103/μL] 8.09 ± 1.50 7.92 ± 1.02 0.127
AST [U/L] 19.3 ± 9.06 21.5 ± 5.8 0.078
Platelet count [× 103/μL] 235 ± 46.4 284 ± 84.8 < 0.001
Hemoglobin [g/dL] 12.8 ± 1.82 14.4 ± 1.42 < 0.001
Creatinine [mg/dL] 0.8 ± 0.13 0.8 ± 0.14 0.181
Total cholesterol [mg/dL] 212 ± 35.2 226 ± 49.2 0.019
LDL-cholesterol [mg/dL] 117 ± 26.9 134 ± 48.4 < 0.001
HDL-cholesterol [mg/dL] 38.8 ± 7.12 33 ± 6.22 < 0.001
SCORE — Systematic Coronary Risk Evaluation; LVEF — left ventricular ejection fraction; SBP — systolic blood pressure; DBP — diastolic blood pressure; WBC — white blood cell; AST — aspartate aminotransferase; 
LDL — low-density lipoprotein; HDL — high-density lipoprotein
Table 1. Clinical, laboratory, and angiographic characteristics of patients according to Systematic Coronary Risk Evaluation (SCORE)
SCORE < 1%
(n = 171)
SCORE ≥ 1% and < 5% 
(n=281) p
Age (years) 44.5 ± 2.39 52.5 ± 5.51 < 0.001
Gender
   Male n (%)




90 (32%) < 0.001
Smoking n (%) 32 (18.7%) 108 (38.4%) < 0.001
LVEF (%) 62.2 ± 3.76 61.9 ± 3.78 0.375
SBP [mm Hg] 143.5 ± 9.07 149 ± 12.5 < 0.001
DBP [mm Hg] 84.5 ± 7.86 89.6 ± 6.93 < 0.001
WBC count [× 103/μL] 7.55 ± 1.39 7.62 ± 1.34 0.867
Platelet count [ ×103/μL] 248 ± 58.7 258 ± 62.9 0.109
Hemoglobin [g/dL] 12.1 ± 1.52 13.4 ± 1.94 < 0.001
Creatinine [mg/dL] 0.8 ± 0.14 0.8 ± 0.15 0.122
AST [U/L] 21.9 ± 8.61 22.6 ± 8.29 0.741
Total cholesterol [mg/dL] 183 ± 35.8 211 ± 38.4 < 0.001
LDL-cholesterol [mg/dL] 93.6 ± 21 118 ± 34.2 < 0.001
HDL-cholesterol [mg/dL] 45.2 ± 6.89 38.6 ± 8 < 0.001
Stenotic CAD 60 (35.1%) 159 (56.6%) < 0.001
Multivessel disease 16 (9.4%) 74(26.3%) < 0.001
SYNTAX score 5.18 ± 7.07 13.5 ± 9.32 < 0.001
LVEF — left ventricular ejection fraction; SBP — systolic blood pressure; DBP — diastolic blood pressure; WBC — white blood cell; AST — aspartate aminotransferase; LDL — low-density lipoprotein;  
HDL — high-density lipoprotein; CAD — coronary artery disease
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Therefore, the results of our study may be helpful for 
further risk stratification of hypertensive patients, 
in particular, for patients without high risk features 
and with suspected CAD. To our knowledge, this is 
the first study to report an independent relationship 
between SCORE and CAD severity in hyperten-
sive patients with low and moderate risk based on 
SCORE system.
There is a consistent link between increased blood 
pressure and coronary atherosclerosis, and hyperten-
sion is the most important modifiable risk factor for 
development and progression of CAD, from endo-
thelial dysfunction to symptomatic obstructive CAD 
[10, 11]. Atherosclerosis is the leading cause of mor-
bidity and mortality in hypertensive patients; how-
ever, the hypertension related coronary atherosclero-
sis generally requires a silent long process, and once 
CAD is emerged, it affects prognosis independently 
[4, 12]. Hereby, early and accurate risk stratification 
remains the cornerstone of the implementation of 
preventive treatments in hypertensive subjects.
SCORE system is a useful tool in clinical prac-
tice considering multiple traditional cardiovascular 
risk factors, and is essential in the risk stratifica-
tion of hypertensive patients [4, 6]. Nevertheless, the 
SCORE system mainly estimates only 10-year risk of 
a first fatal atherosclerotic cardiovascular event, and 
its predictive value regarding non-fatal events is not 
well described. However, due to the nature of the 
SCORE system consisting five important risk factors 
for CAD, it is reasonable to consider that it may be 
associated with various cardiovascular end points, 
and may be more helpful than expected in clinical 
practice.
Since the combination of the traditional cardio-
vascular risk factors predicts atherosclerosis more 
accurately, risk scores play an essential role in the 
estimation of total cardiovascular risk and subse-
quent implementation of preventive managements 
[13]. Cardiovascular risk scores including SCORE 
system have been shown to be associated with CAD 
severity in small studies conducted in unselected 
patients underwent coronary angiography, mainly 
due to high risk features [14–16]. However, no study 
investigated the association of SCORE system with 
CAD severity in isolated hypertensive patients with 
low and moderate risk. We determined a significant 
positive correlation between SCORE and CAD se-
verity, and also found that hypertensive patients at 
moderate risk had significantly more severe CAD 
compared to those at low risk according to SCORE 
Table 3. Multivariate logistic regression analysis for independent predictors of stenotic coronary artery disease (CAD), multivessel disease 
and SYNTAX score > 22
Variable OR 95% CI p
Stenotic CAD
SCORE 1.616 1.055–1.901 < 0.001
LDL-cholesterol 1.162 1.034–1.290 < 0.001
DBP 1.068 1.040–1.130 < 0.001
Multivessel disease
SCORE 1.913 1.545–2.091 < 0.001
LDL-cholesterol 1.171 1.098–1.570 < 0.001
SYNTAX score > 22
SCORE 1.817 1.438–2.253 < 0.001
LDL-cholesterol 1.079 1.037–1.492 < 0.001
CAD — coronary artery disease; SCORE — Systematic Coronary Risk Evaluation; LDL — low-density lipoprotein; DBP — diastolic blood pressure; OR — odds ratio; CI — confidence interval
Figure 1. Receiver operating characteristic (ROC) curve analysis of 
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system. Hereby, our results point out the importance 
of further risk assessment of hypertensive patients, 
even if they are considered as low or, in particular, 
moderate risk according to SCORE system.
The main clinical importance of risk assessment 
by SCORE is its essential role in the providing suc-
cessful prevention of future events [4, 6]. Primary 
prevention methods including drug treatment reduce 
major cardiovascular events in patients at high risk or 
very high risk according to SCORE (SCORE ≥ 5%) 
[6, 17]. Hence, these patients generally receive opti-
mal preventive treatments without need for further 
risk assessment. However, preventive treatment with 
drugs are not generally recommended for patients 
at low to moderate risk (SCORE < 5%), and these 
patients are usually offered lifestyle advice to main-
tain their low to moderate risk status [6]. On the 
other hand, the findings of the present article suggest 
that a selected subgroup of hypertensive patients at 
moderate risk according to SCORE system may be 
considered as patients at relatively high risk and may 
provide more benefit from preventive treatments. 
Consequently, widening the preventive methods for 
hypertensive patients with suspected CAD and at 
moderate risk according to SCORE system may be 
useful for an optimal primary prevention. Neverthe-
less, there is lack of data regarding the clinical benefit 
of preventive treatments in moderate risk hyperten-
sive patients, and future studies investigating this 
topic are necessary. In this sense, the key point of the 
present study is that SCORE may be useful for fur-
ther risk stratification in hypertensive patients even 
in the absence of high risk features.
The present study has some limitations. First, the 
study included a selected patient population between 
the age 40 and 65. Therefore, it is difficult to general-
ize our findings to hypertensive patients that are out 
of this age range. However, the SCORE system is 
validated for hypertensive subjects between the age 
40 and 65, and this age range includes the vast ma-
jority of patients that will benefit from the preven-
tive treatments. Second, although we excluded the 
patients with asymptomatic hypertension-mediated 
organ damage, there may be still some other clinical 
factors that increase the patients’ risk independently. 
Conclusions
The SCORE system may be useful in further risk 
stratification of hypertensive patients who have 
moderate risk features and are suspected of CAD. 
Our study suggests that SCORE has an indepen-
dent relationship and positive correlation with SYN-
TAX score, in particular in patients at moderate 
risk, which may affect the prognosis independently. 
Therefore, SCORE may be useful in the discrimina-
tion of hypertensive patients at relatively high risk 
even if they are assigned as moderate risk according 
to SCORE system. Further risk assessment in this 
selected subgroup of hypertensive patients with sus-
pected CAD may lead a more adequate preventive 
program and treatment.
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